BCI
ORKA

Brinker Capital Investments’s Oruka Therapeutics ORKA Stock Holding History

Brinker Capital Investments’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$554K Sell
5,825
-1,404
-19% -$93.5K ﹤0.01% 1417
2026
Q1 		$355K Buy
+7,229
New +$251K ﹤0.01% 1597

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Brinker Capital Investments's ORKA Position: Q2 2026 in Review

Brinker Capital Investments reduced its Oruka Therapeutics (ORKA) stake by 19% in Q2 2026, selling an estimated $93.5K and leaving 5,825 shares worth $554K. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Brinker Capital Investments first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Brinker Capital Investments held 5,825 shares of Oruka Therapeutics worth $554K as of Q2 2026.
  • Brinker Capital Investments sold 1,404 Oruka Therapeutics shares in Q2 2026, an estimated $93.5K.
  • Oruka Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1417 holding.
  • Brinker Capital Investments first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.